Market Research Report
Acute Kidney Injury (AKI) - Market Insight, Epidemiology and Market Forecast -2030
|Published by||DelveInsight Business Research LLP||Product code||736663|
|Published||Pre-Order||Content info||200 Pages
Delivery time: 10 business days
|Acute Kidney Injury (AKI) - Market Insight, Epidemiology and Market Forecast -2030|
|Published: Pre-Order||Content info: 200 Pages||
DelveInsight's 'Acute Kidney Injury (AKI) -Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Acute Kidney Injury (AKI), historical and forecasted epidemiology as well as the Acute Kidney Injury (AKI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Acute Kidney Injury (AKI) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Kidney Injury (AKI) market size from 2017 to 2030. The report also covers current Acute Kidney Injury (AKI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Acute Kidney Injury (AKI) Overview
AKI is characterized by a rapid fall in glomerular filtration rate, clinically manifest as an abrupt and sustained rise in urea and creatinine. Life threatening consequences include volume overload, hyperkalaemia, and metabolic acidosis. As per the American Kidney Foundation organization, AKI was formerly called Acute Kidney Injury. The disease leads to abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes. Acute Kidney Injury is classified into three different phases including prerenal, postrenal and intrinsic renal. Pre-renal ARI is characterized by inadequate blood circulation to the kidneys, which leaves them to clean the body properly. Post-renal is characterized by acute obstruction to urinary flow which increases intratubular pressure and decreases GFR. Intrinsic AKI is the third type, which shows direct damage to kidneys by inflammation, toxins, drugs, and infections. The risk factors associated with AKI include age, exposure to nephrotoxins, family history, race and ethnicity, gender and others.
The DelveInsight Acute Kidney Injury market report gives the thorough understanding of the AKI by including details such as disease introduction, signs and symptoms, types of AKI, risk factors, causes, pathophysiology, stages of classification, biomarkers and diagnosis. It also provides treatment algorithms and treatment guidelines for AKI in the US, Europe, and Japan.
Acute Kidney Injury (AKI) Diagnosis
The diagnosis of AKI is traditionally based on a rise in serum creatinine and/or fall in urine output. The definition has evolved from the Risk, Injury, Failure, Loss, End-stage (RIFLE) criteria in 2004 to the AKI Network (AKIN) classification in 2007. In 2012, both were merged resulting in the Kidney Disease Improving Global Outcomes (KDIGO) classification. Accordingly, AKI is diagnosed if serum creatinine increases by 0.3 mg/dl (26.5 μmol/l) or more in 48 h or rises to at least 1.5-fold from baseline within 7 days. AKI stages are defined by the maximum change of either serum creatinine or urine output. The importance of both criteria was confirmed in a recent study in >32,000 critically ill patients which showed that short- and long-term risk of death or renal replacement therapy (RRT) were greatest when patients met both criteria for AKI and when these abnormalities persisted for longer than 3 days.
For diagnosing the disease, a patient history and physical examination are very crucial. The history should identify the use of nephrotoxic medications or systemic illnesses that might cause poor renal perfusion or directly impair renal function. Physical examination should assess intravascular volume status and any skin rashes indicative of systemic illness. The initial laboratory evaluation should include urinalysis, complete blood count, and measurement of serum creatinine level and fractional excretion of sodium. There are some tests which are generally used to diagnose the disease.
Acute Kidney Injury (AKI) Treatment
Management and treatment landscape of acute kidney injury involves fluid resuscitation, avoidance of nephrotoxic medications and contrast media exposure, and correction of electrolyte imbalances. Renal replacement therapy (dialysis) is indicated for refractory hyperkalemia; volume overload; intractable acidosis; uremic encephalopathy, pericarditis, or pleuritis; and removal of certain toxins. Recognition of risk factors (e.g., older age, sepsis, hypovolemia/shock, cardiac surgery, infusion of contrast agents, diabetes mellitus, preexisting chronic kidney disease, cardiac failure, liver failure) is important. Team-based approaches for prevention, early diagnosis, and aggressive management are critical for improving outcomes.
Supportive therapies (e.g., antibiotics, maintenance of adequate nutrition, mechanical ventilation, glycemic control, anemia management) should be pursued based on standard management practices. In patients with rapidly progressive glomerulonephritis, treatment with pulse steroids, cytotoxic therapy, or a combination may be considered, often after confirmation of the diagnosis by kidney biopsy
It covers the details of conventional and current medical therapies available in the AKI market for the treatment of the various types of AKI. It also provides the treatment guidelines and algorithms of the United States and Europe. The DelveInsight's Acute Kidney Injury (AKI) market report gives a thorough understanding of Acute Kidney Injury (AKI) by including details such as disease introduction, causes, risk factors, pathogenesis, and diagnosis.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of Acute Kidney Injury, Discharge Diagnosed Cases of Acute Kidney Injury, Stage-Wise Discharged Diagnosed Cases of Acute Kidney Injury, Risk Factor Associated Acute Kidney Injury Cases and Renal Transplantation Associated Delayed Graft Function scenario of Acute Kidney Injury (AKI) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
This section provides glimpse of the Acute Kidney Injury (AKI) epidemiology in the 7MM.
The epidemiology segment also provides the Acute Kidney Injury (AKI) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The drug chapter segment of the AKI report encloses the detailed analysis of mid and late stage pipeline drugs. It also helps to understand the AKI clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Acute Kidney Injury (AKI) Emerging Drugs
EA-230: Exponential Biotherapies
EA-230 is being developed by Exponential Biotherapies, is an intravenously administered chemically synthesized linear peptide, a derivative of the human pregnancy hormone used for immunomodulation. During the preclinical studies, the drug has shown anti-inflammatory properties and protects against organ failure in several animal models of sepsis or systemic inflammation which lead to acute kidney injury. Most notably, EA-230 has shown marked protective effects in the kidney during abdominal sepsis in animals. As EA-230 attenuates the proinflammatory response in neutrophils and monocytes ex vivo, and neutrophil influx in tissues during systemic inflammation in vivo is abrogated, EA-230 acts by protecting the host against the detrimental effects of neutrophils during acute systemic inflammatory diseases, thereby preventing organ damage, especially in the kidney. EA-230 is under development by Exponential Biotherapies in collaboration with Radboud University.
Product detail in the report…
RESCAP (Rescuing Alkaline Phosphatase), is an endogenous enzyme based on Alkaline Phosphatase (AP) a naturally occurring protein present in the body. It works as prophylactic and therapeutic anti-inflammatory protein that prevents ischemic injury by neutralizing and detoxifying inflammatory triggers that may derail the immune system. In acute settings, RESCAP triggers enhanced endogenous production of AP by the body, thereby boosting innate defense systems. bRESCAP is the type of RESCAP based on calf intestine from BSE free countries. It has a fast onset of action, a high dosing efficacy and a short residence time in the body (half-life of a few minutes), which makes the drug ideal for acute clinical disorder treatments.
ANG-3777 (BB3): Angion Biomedica
ANG-3777 (also known as BB3 and refanalin) is a small molecule hepatocyte growth factor/scatter factor (HGF/SF) being developed by Angion Biomedica. Its development is grounded in decades of research investigating the role of the HGF/c-Met pathway in organ repair. When an organ is injured, HGF expression peaks around 2 h but c-Met receptor expression peaks around 24-36 h, creating a mismatch between HGF and c-Met potentially resulting in suboptimal rates of organ self-repair. ANG-3777 is designed to address this challenging mismatch, supplementing endogenous HGF during peak c-MET receptor expression.
Product detail in the report…
Teprasiran (QPI-1002): Quark Pharmaceuticals
Teprasiran (QPI-1002) is a nuclease-resistant, synthetic double-stranded RNA oligonucleotide designed to temporarily inhibit the expression of the proapoptotic gene p53, via activation of the RNA interference (RNAi) pathway being developed by Quark Pharmaceuticals. Its development is based on the proprietary concept for temporary and reversible inhibition of p53 for therapeutic purposes. P53 is a stress-response gene activated by DNA damage, hypoxia, oxidative stress, and other conditions, leading to the induction of cell cycle arrest, cell senescence or apoptosis.
Product detail in the report…
ASP1128: Astellas Pharma
ASP1128 by Astellas Pharma is also known as MA-0217, is an investigational compound that is a potent and highly selective PPARδ modulator. ASP1128 has the potential to have protective effects on kidney cells that are under cellular stress following CABG/V surgery by promoting fatty acid oxidation in the mitochondria. Further, ASP1128 may have the potential to reduce systemic and local inflammatory responses and oxidative stress.
Product detail in the report…
Acute kidney injury (AKI) or acute renal failure (AKI) is a condition characterized by minor or complete loss of kidney function due to a sudden injury to kidneys. AKI is different from chronic kidney disease, wherein the kidney function is lost over a period of time. The disease generally occurs as a complication of another serious disease and is more common in the geriatric population that suffers from various other diseases. The global burden of acute kidney injury has increased over the years. Among the 7 major markets, the United States has reported having maximum incident cases of AKI. Though the incident of AKI is high across the US, but the condition is often undiagnosed, ultimately leading to lower treatable pool (when compared to the total incident population of the disease) that contributes to the market size of AKI.
Currently there are no targeted pharmacotherapies approved for the treatment of AKI. At present, the therapeutic market size of acute kidney injury in the United States is mainly accounted by use of Renal Replacement Therapy (RRT) and off-label drugs which includes various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
The AKI market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted AKI market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of AKI market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, AKI 7MM market is expected to change in the study period 2017-2030.
This section includes a glimpse of the Acute Kidney Injury (AKI) 7MM market.
This section provides the total Acute Kidney Injury (AKI) market size and market size by therapies in the United States.
The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Acute Kidney Injury (AKI) market size and market size by therapies in Japan are provided.
This section focusses on the rate of uptake of the potential drugs that are expected to get launched in the market during the study period 2017-2030. The analysis covers Acute Kidney Injury (AKI) market uptake by drugs and patient uptake by therapies.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Acute Kidney Injury (AKI) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Acute Kidney Injury (AKI) emerging therapies.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Acute Kidney Injury (AKI) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Current Treatment Scenario, Marketed Drugs and Emerging Therapies: